In today’s recent session, 0.42 million shares of the AN2 Therapeutics Inc (NASDAQ:ANTX) have been traded, and its beta is -0.20. Most recently the company’s share price was $1.11, and it changed around $0.01 or 0.91% from the last close, which brings the market valuation of the company to $33.12M. ANTX at last check was trading at a discount to its 52-week high of $22.22, offering almost -1901.8% off that amount. The share price’s 52-week low was $0.87, which indicates that the recent value has risen by an impressive 21.62% since then. We note from AN2 Therapeutics Inc’s average daily trading volume that its 10-day average is 1.43 million shares, with the 3-month average coming to 552.34K.

AN2 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended ANTX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. AN2 Therapeutics Inc is expected to report earnings per share of -0.37 for the current quarter.

AN2 Therapeutics Inc (NASDAQ:ANTX) trade information

Instantly ANTX has been showing a green trend so far today with a performance of 0.91% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.1300 on recent trading dayincreased the stock’s daily price by 1.77%. The company’s shares are currently down -94.58% year-to-date, but still up 5.71% over the last five days. On the other hand, AN2 Therapeutics Inc (NASDAQ:ANTX) is -58.58% down in the 30-day period. We can see from the shorts that 0.68 million shares have been sold at a short interest cover period of 3.47 day(s).

The consensus price target as assigned by Wall Street analysts is $5.5, which translates to bulls needing to increase their stock price by 79.82% from its current value. Analyst projections state that ANTX is forecast to be at a low of $2 and a high of $22.

AN2 Therapeutics Inc (ANTX) estimates and forecasts

AN2 Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -64.54 percent over the past six months and at a 29.20% annual growth rate that is well above the industry average of 18.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 43.10% in revenue this quarter, and will report an increase of 49.10% in the next quarter.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -73.03%.

ANTX Dividends

AN2 Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Aug-13.

AN2 Therapeutics Inc (NASDAQ:ANTX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 25.36% of AN2 Therapeutics Inc shares, and 72.82% of them are in the hands of institutional investors. The stock currently has a share float of 97.56%. AN2 Therapeutics Inc stock is held by 59.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 18.6515% of the shares, which is about 5.55 million shares worth $11.94 million.

OCTAGON CAPITAL ADVISORS LP, with 10.8196% or 3.22 million shares worth $6.92 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2024. The former held 749.42 shares worth $0.83 million, making up 2.51% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 261.93 shares worth around $0.29 million, which represents about 0.88% of the total shares outstanding.